Clear cell renal cell carcinoma: Discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT

Jonathan R Young, Daniel Margolis, Steven Sauk, Allan J. Pantuck, James Sayre, Steven S. Raman

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

Purpose: To determine whether enhancement at multiphasic multidetector computed tomography (CT) can help differentiate clear cell renal cell carcinoma (RCC) from oncocytoma, papillary RCC, and chromophobe RCC. Materials and Methods: With institutional review board approval for this HIPAAcompliant retrospective study, the pathology database was queried to derive a cohort of 298 cases of RCC and oncocytoma with preoperative multiphasic multidetector CT with as many as four phases (unenhanced, corticomedullary, nephrographic, and excretory). A total of 170 clear cell RCCs, 57 papillary RCCs, 49 oncocytomas, and 22 chromophobe RCCs were evaluated for multiphasic enhancement and compared by using t tests. Cutoff analysis was performed to determine optimal threshold levels to discriminate among the four groups. Results: Mean enhancement of clear cell RCCs and oncocytomas peaked in the corticomedullary phase; mean enhancement of papillary and chromophobe RCCs peaked in the nephrographic phase. Enhancement of clear cell RCCs was greater than that of oncocytomas in the corticomedullary (125 HU vs 106 HU, P = .045) and excretory (80 HU vs 67 HU, P = .034) phases. Enhancement of clear cell RCCs was greater than that of papillary RCCs in the corticomedullary (125 HU vs 54 HU, P < .001) , nephrographic (103 HU vs 64 HU, P < .001) , and excretory (80 HU vs 54 HU, P < .001) phases. Enhancement of clear cell RCCs was greater than that of chromophobe RCCs in the corticomedullary (125 HU vs 74 HU, P < .001) and excretory (80 HU vs 60 HU, P = .008) phases. Thresholding of enhancement helped to discriminate clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC with accuracies of 77% (83 of 108 cases), 85% (101 of 119 cases), and 84% (81 of 97 cases). Conclusion: Enhancement at multiphasic multidetector CT, if prospectively validated, may assist in the discrimination of clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC.

Original languageEnglish (US)
Pages (from-to)444-453
Number of pages10
JournalRadiology
Volume267
Issue number2
DOIs
StatePublished - May 1 2013
Externally publishedYes

Fingerprint

Oxyphilic Adenoma
Multidetector Computed Tomography
Renal Cell Carcinoma
Research Ethics Committees
Retrospective Studies
Clear-cell metastatic renal cell carcinoma
Databases
Pathology

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Clear cell renal cell carcinoma : Discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT. / Young, Jonathan R; Margolis, Daniel; Sauk, Steven; Pantuck, Allan J.; Sayre, James; Raman, Steven S.

In: Radiology, Vol. 267, No. 2, 01.05.2013, p. 444-453.

Research output: Contribution to journalArticle

Young, Jonathan R ; Margolis, Daniel ; Sauk, Steven ; Pantuck, Allan J. ; Sayre, James ; Raman, Steven S. / Clear cell renal cell carcinoma : Discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT. In: Radiology. 2013 ; Vol. 267, No. 2. pp. 444-453.
@article{a927f30a5946492e9e60c79273ee3e21,
title = "Clear cell renal cell carcinoma: Discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT",
abstract = "Purpose: To determine whether enhancement at multiphasic multidetector computed tomography (CT) can help differentiate clear cell renal cell carcinoma (RCC) from oncocytoma, papillary RCC, and chromophobe RCC. Materials and Methods: With institutional review board approval for this HIPAAcompliant retrospective study, the pathology database was queried to derive a cohort of 298 cases of RCC and oncocytoma with preoperative multiphasic multidetector CT with as many as four phases (unenhanced, corticomedullary, nephrographic, and excretory). A total of 170 clear cell RCCs, 57 papillary RCCs, 49 oncocytomas, and 22 chromophobe RCCs were evaluated for multiphasic enhancement and compared by using t tests. Cutoff analysis was performed to determine optimal threshold levels to discriminate among the four groups. Results: Mean enhancement of clear cell RCCs and oncocytomas peaked in the corticomedullary phase; mean enhancement of papillary and chromophobe RCCs peaked in the nephrographic phase. Enhancement of clear cell RCCs was greater than that of oncocytomas in the corticomedullary (125 HU vs 106 HU, P = .045) and excretory (80 HU vs 67 HU, P = .034) phases. Enhancement of clear cell RCCs was greater than that of papillary RCCs in the corticomedullary (125 HU vs 54 HU, P < .001) , nephrographic (103 HU vs 64 HU, P < .001) , and excretory (80 HU vs 54 HU, P < .001) phases. Enhancement of clear cell RCCs was greater than that of chromophobe RCCs in the corticomedullary (125 HU vs 74 HU, P < .001) and excretory (80 HU vs 60 HU, P = .008) phases. Thresholding of enhancement helped to discriminate clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC with accuracies of 77{\%} (83 of 108 cases), 85{\%} (101 of 119 cases), and 84{\%} (81 of 97 cases). Conclusion: Enhancement at multiphasic multidetector CT, if prospectively validated, may assist in the discrimination of clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC.",
author = "Young, {Jonathan R} and Daniel Margolis and Steven Sauk and Pantuck, {Allan J.} and James Sayre and Raman, {Steven S.}",
year = "2013",
month = "5",
day = "1",
doi = "10.1148/radiol.13112617",
language = "English (US)",
volume = "267",
pages = "444--453",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "2",

}

TY - JOUR

T1 - Clear cell renal cell carcinoma

T2 - Discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT

AU - Young, Jonathan R

AU - Margolis, Daniel

AU - Sauk, Steven

AU - Pantuck, Allan J.

AU - Sayre, James

AU - Raman, Steven S.

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Purpose: To determine whether enhancement at multiphasic multidetector computed tomography (CT) can help differentiate clear cell renal cell carcinoma (RCC) from oncocytoma, papillary RCC, and chromophobe RCC. Materials and Methods: With institutional review board approval for this HIPAAcompliant retrospective study, the pathology database was queried to derive a cohort of 298 cases of RCC and oncocytoma with preoperative multiphasic multidetector CT with as many as four phases (unenhanced, corticomedullary, nephrographic, and excretory). A total of 170 clear cell RCCs, 57 papillary RCCs, 49 oncocytomas, and 22 chromophobe RCCs were evaluated for multiphasic enhancement and compared by using t tests. Cutoff analysis was performed to determine optimal threshold levels to discriminate among the four groups. Results: Mean enhancement of clear cell RCCs and oncocytomas peaked in the corticomedullary phase; mean enhancement of papillary and chromophobe RCCs peaked in the nephrographic phase. Enhancement of clear cell RCCs was greater than that of oncocytomas in the corticomedullary (125 HU vs 106 HU, P = .045) and excretory (80 HU vs 67 HU, P = .034) phases. Enhancement of clear cell RCCs was greater than that of papillary RCCs in the corticomedullary (125 HU vs 54 HU, P < .001) , nephrographic (103 HU vs 64 HU, P < .001) , and excretory (80 HU vs 54 HU, P < .001) phases. Enhancement of clear cell RCCs was greater than that of chromophobe RCCs in the corticomedullary (125 HU vs 74 HU, P < .001) and excretory (80 HU vs 60 HU, P = .008) phases. Thresholding of enhancement helped to discriminate clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC with accuracies of 77% (83 of 108 cases), 85% (101 of 119 cases), and 84% (81 of 97 cases). Conclusion: Enhancement at multiphasic multidetector CT, if prospectively validated, may assist in the discrimination of clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC.

AB - Purpose: To determine whether enhancement at multiphasic multidetector computed tomography (CT) can help differentiate clear cell renal cell carcinoma (RCC) from oncocytoma, papillary RCC, and chromophobe RCC. Materials and Methods: With institutional review board approval for this HIPAAcompliant retrospective study, the pathology database was queried to derive a cohort of 298 cases of RCC and oncocytoma with preoperative multiphasic multidetector CT with as many as four phases (unenhanced, corticomedullary, nephrographic, and excretory). A total of 170 clear cell RCCs, 57 papillary RCCs, 49 oncocytomas, and 22 chromophobe RCCs were evaluated for multiphasic enhancement and compared by using t tests. Cutoff analysis was performed to determine optimal threshold levels to discriminate among the four groups. Results: Mean enhancement of clear cell RCCs and oncocytomas peaked in the corticomedullary phase; mean enhancement of papillary and chromophobe RCCs peaked in the nephrographic phase. Enhancement of clear cell RCCs was greater than that of oncocytomas in the corticomedullary (125 HU vs 106 HU, P = .045) and excretory (80 HU vs 67 HU, P = .034) phases. Enhancement of clear cell RCCs was greater than that of papillary RCCs in the corticomedullary (125 HU vs 54 HU, P < .001) , nephrographic (103 HU vs 64 HU, P < .001) , and excretory (80 HU vs 54 HU, P < .001) phases. Enhancement of clear cell RCCs was greater than that of chromophobe RCCs in the corticomedullary (125 HU vs 74 HU, P < .001) and excretory (80 HU vs 60 HU, P = .008) phases. Thresholding of enhancement helped to discriminate clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC with accuracies of 77% (83 of 108 cases), 85% (101 of 119 cases), and 84% (81 of 97 cases). Conclusion: Enhancement at multiphasic multidetector CT, if prospectively validated, may assist in the discrimination of clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC.

UR - http://www.scopus.com/inward/record.url?scp=84876907476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876907476&partnerID=8YFLogxK

U2 - 10.1148/radiol.13112617

DO - 10.1148/radiol.13112617

M3 - Article

C2 - 23382290

AN - SCOPUS:84876907476

VL - 267

SP - 444

EP - 453

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 2

ER -